Medtronic plc (NYSE:MDT) Stock Position Decreased by Connor Clark & Lunn Investment Management Ltd.

by · The Cerbat Gem

Connor Clark & Lunn Investment Management Ltd. cut its stake in shares of Medtronic plc (NYSE:MDT – Free Report) by 74.0% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 337,760 shares of the medical technology company’s stock after selling 961,552 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Medtronic were worth $30,409,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of MDT. Olstein Capital Management L.P. grew its position in Medtronic by 19.2% during the 3rd quarter. Olstein Capital Management L.P. now owns 87,000 shares of the medical technology company’s stock worth $7,833,000 after purchasing an additional 14,000 shares in the last quarter. Manning & Napier Advisors LLC acquired a new position in Medtronic during the second quarter valued at $25,643,000. Ferguson Wellman Capital Management Inc. acquired a new position in Medtronic during the third quarter valued at $9,486,000. Harvest Portfolios Group Inc. lifted its stake in Medtronic by 6.5% in the 3rd quarter. Harvest Portfolios Group Inc. now owns 689,131 shares of the medical technology company’s stock worth $62,042,000 after acquiring an additional 42,112 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its position in Medtronic by 6.3% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 368,682 shares of the medical technology company’s stock worth $29,019,000 after acquiring an additional 21,995 shares during the period. 82.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Needham & Company LLC reissued a “hold” rating on shares of Medtronic in a research report on Monday. Wells Fargo & Company cut their target price on shares of Medtronic from $106.00 to $98.00 and set an “overweight” rating for the company in a research report on Wednesday. JPMorgan Chase & Co. lowered their price target on Medtronic from $99.00 to $96.00 and set a “neutral” rating for the company in a research note on Friday, November 15th. Daiwa America raised shares of Medtronic to a “strong-buy” rating in a research report on Friday, August 23rd. Finally, Royal Bank of Canada raised Medtronic from a “sector perform” rating to an “outperform” rating and boosted their price target for the stock from $98.00 to $105.00 in a research report on Thursday, October 10th. One analyst has rated the stock with a sell rating, nine have issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $95.19.

View Our Latest Stock Analysis on MDT

Medtronic Stock Down 1.0 %

MDT opened at $84.11 on Thursday. The business has a 50 day moving average of $89.17 and a 200-day moving average of $84.84. The stock has a market capitalization of $107.87 billion, a price-to-earnings ratio of 25.72, a P/E/G ratio of 2.50 and a beta of 0.84. The company has a current ratio of 2.13, a quick ratio of 1.61 and a debt-to-equity ratio of 0.55. Medtronic plc has a 1-year low of $75.96 and a 1-year high of $92.68.

Medtronic (NYSE:MDT – Get Free Report) last issued its quarterly earnings results on Tuesday, November 19th. The medical technology company reported $1.26 earnings per share for the quarter, beating analysts’ consensus estimates of $1.25 by $0.01. Medtronic had a net margin of 12.06% and a return on equity of 13.68%. The firm had revenue of $8.40 billion during the quarter, compared to the consensus estimate of $8.27 billion. During the same period in the prior year, the firm earned $1.25 EPS. The business’s revenue was up 5.2% on a year-over-year basis. As a group, sell-side analysts anticipate that Medtronic plc will post 5.44 earnings per share for the current year.

Medtronic Company Profile

(Free Report)

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

See Also